InvestmentAug 3, 2026, 07:03 AM
Cocrystal Pharma Receives $5M Investment from OPKO Health
AI Summary
Cocrystal Pharma announced a $5 million investment from OPKO Health, a longtime investor, increasing its position in the company. Cocrystal sold 5,474,053 shares of common stock to OPKO at $0.9134 per share. This investment will help advance Cocrystal's lead norovirus program, CDI-988, with Phase 1b topline data anticipated by the end of the fourth quarter of 2026.
Key Highlights
- OPKO Health invested $5 million in Cocrystal Pharma.
- Cocrystal Pharma sold 5,474,053 shares of common stock to OPKO.
- The shares were sold at a price of $0.9134 per share.
- The investment will support the norovirus Phase 1b program.
- Topline data from the Phase 1b norovirus trial is expected by Q4 2026.
Price Impact
More from COCP